Search | OpenScholar

Search results

376 results found

Communicating with participants during the conduct of multi-center clinical trials. Clin Trials 2016;13:592-596.

Publication: Journal Article

Augustine, EF, ER Dorsey, RA Hauser, JJ Elm, BC Tilley, and KK Kieburtz. 2016. “Communicating With Participants During the Conduct of Multi-Center Clinical Trials. Clin Trials 2016;13:592-596.”. Clin Trials.

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol 2016;263:772-780.

Publication: Journal Article

Han, Y, AL Stevens, K Dashtipour, RA Hauser, and Z Mari. 2016. “A Mixed Treatment Comparison to Compare the Efficacy and Safety of Botulinum Toxin Treatments for Cervical Dystonia. J Neurol 2016;263:772-780.”. J Neurol .

Levodopa-carbidopa intestinal gelin advanced Parkinson's disease: Final 12-month, open-label results. Mov Disord 2015;30:500-9.

Publication: Journal Article

Fernandez, HH, DG Standaert, RA Hauser, AE Lang, VS Fung, F Klostermann, MF Lew, et al. 2015. “Levodopa-Carbidopa Intestinal Gelin Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord 2015;30:500-9.”. Mov Disord.

α-Synuclein in Parkinson's disease: getting to the core of the matter. Lancet Neurol 2015;14:785-6.

Publication: Journal Article

Hauser, RA. 2015. “α-Synuclein in Parkinson’s Disease: Getting to the Core of the Matter. Lancet Neurol 2015;14:785-6.”. Lancet Neurol.

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015;72:1491-500.

Publication: Journal Article

Hauser, RA, F Stocchi, O Rascol, SB Huyck, R Capece, TW Ho, P Sklar, C Lines, D Michelson, and D Hewitt. 2015. “Preladenant As an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol 2015;72:1491-500.”. JAMA Neurol.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord 2015;30:1371-81.

Publication: Journal Article

Simuni, T, C Caspell-Garcia, C Coffey, LM Chahine, S Lasch, WH Oertel, G Mayer, et al. 2015. “Correlates of Excessive Daytime Sleepiness in de Novo Parkinson’s Disease: A Case Control Study. Mov Disord 2015;30:1371-81.”. Mov Disord.

Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A). J Parkinsons Dis 2014;4:57-65.

Publication: Journal Article

Hauser, RA, LA Arthur Hewitt, and S Isaacson. 2014. “Droxidopa in Patients With Neurogenic Orthostatic Hypotension Associated With Parkinson’s Disease (NOH306A). J Parkinsons Dis 2014;4:57-65.”. J Parkinsons Dis.

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014;29:75-82.

Publication: Journal Article

LeWitt, PA, FJ Huff, RA Hauser, D Chen, D Lissin, K Zomorodi, and KC Cundy. 2014. “Double-Blind Study of the Actively Transported Levodopa Prodrug XP21279 in Parkinson’s Disease. Mov Disord 2014;29:75-82.”. Mov Disord.

Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014;20:1171-6.

Publication: Journal Article

Hauser, RA, S Isaacson, T Clinch, and Tigan/Apokyn Study Investigators. 2014. “Randomized, Placebo-Controlled Trial of Trimethobenzamide to Control Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine Injection. Parkinsonism Relat Disord 2014;20:1171-6.”. Parkinsonism Relat Disord.

Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol 2013;20:180-7.

Publication: Journal Article

AH, Schapira, P Barone, RA Hauser, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2013. “Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Release Pramipexole in Advanced Parkinson’s Disease. Eur J Neurol 2013;20:180-7.”. Eur J Neurol.